Trial Profile
Post-Licensure Observational Study of the Safety of GARDASIL in Males.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 12 Nov 2022 Results assessing the risk of new onset autoimmune conditions among males receiving the 4-valent human papillomavirus (HPV) vaccine (4vHPV), published in the Vaccine.
- 20 Jun 2019 Status changed from active, no longer recruiting to completed.
- 10 May 2019 Planned End Date changed from 1 Apr 2020 to 1 Jun 2019.